Hydroxyethyl starches (HES) are almost exclusively excreted glomerularly, in part after hydrolysis by amylase. HES 130/0.4 (Voluven ® ; Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany) was developed to improve pharmacokinetics whereas preserving the efficacy of volume effect. We studied the dependency of pharmacokinetics of HES 130/0.4 on renal function. Nineteen volunteers with stable, nonanuric renal dysfunction, ranging from almost normal creatinine clearance (CL cr ) to severe renal impairment (mean CL cr : 50.6 mL · min Ϫ1 · 1.73 m Ϫ2 ), were given a single infusion of 500 mL 6% HES 130/0.4 over 30 min. HES plasma concentrations were determined until 72 h, urinary excretion until 72-96 h. CL cr had been obtained at least twice before and twice after dosing. Standard pharmacokinetic calculations and regression analysis were performed. Area under the time concentration curve (AUC 0 -inf ) clearly depended on renal function comparing subjects with CL cr Ͻ50 with those with CL cr Ն50 (ratio 1.73). Peak concentration (C max , 4.34 mg/ mL) as well as terminal half-life (16.1 h, model independent) were not affected by renal impairment. At CL cr Ն30, 59% of the drug could be retrieved in urine, versus 51% at CL cr 15-Ͻ30. The mean molecular weight of HES in plasma was 62,704 d at 30 min, showing lower values with increased renal impairment (P ϭ 0.04). Predose amylase concentrations inversely correlated with baseline CL cr . Residual HES plasma concentrations after 24 h were small in all subjects (Յ0.6 mg/mL). We conclude that HES 130/0.4 (500 mL 6%) can be safely administered to patients even with severe renal impairment, as long as urine flow is preserved, without plasma accumulation.
H ydroxyethyl starch (HES) solutions are artificial colloids for intravascular volume replacement derived from corn starch amylopectin. HES solutions are polydisperse, comprising a distribution of molecular sizes. The polyglucose chains closely resemble glycogen with predominant ␣1-4 bindings. The main characteristics of a HES type are mean molecular weight (Mw, weight average), molar substitution (MS, i.e., mol hydroxyethyl residues per mol glucose subunits), and C2/C6 ratio (the substitution pattern at the glucose subunit carbon atoms). There are large regional differences in the use of different HES specifications. For decades in the United States, only HES 450/0.7 has been available for volume therapy. The predominant starch in Europe is HES 200/0.5, whereas in Japan only HES 70/0.5 is available. Safety issues of a colloid such as HES are related to molecular properties, resulting in different in vivo Mw, plasma concentrations over time, and tissue storage. Pharmacology, especially regarding half-lives, duration of volume effect, posology, and possible side effects, significantly differs among the different specifications.
However, all HES preparations are excreted renally. Other ways of excretion are negligible (1) . Molecules above the renal threshold are filtered glomerularly only after hydrolysis by serum ␣-amylase to smaller fragments. A new medium-Mw starch specification, HES 130/0.4 (6%, Voluven ® ), was developed to improve pharmacokinetics by more rapid metabolism whereas preserving the efficacy of volume effect compared with HES 200/0.5 (6%). The pharmacologic characteristics of HES 130/0.4 are a Mw of 130,000 Ϯ 20,000 d, an MS of 0.4, and a C 2 /C 6 ratio of about 9:1, leading to a decrease in plasma accumulation (2) and a smaller tissue storage (3) of HES after repeated administration. The Mw distribution was narrowed by the reduction of the high-and low-Mw fraction, which led to an increase of the medium-size fraction, with most of these molecules above the renal threshold. A low MS results in an increase of metabolic degradation (4) . However, the increased C 2 /C 6 ratio in part counteracts this effect, because a high C 2 /C 6 ratio decreases the hydrolysis by ␣-amylase (5, 6) . In addition to studies in patients that demonstrated efficacy and a favorable safety profile (7) (8) (9) (10) (11) (12) (13) , pharmacokinetic trials in healthy volunteers showed a rapid elimination from plasma after both single- (14) and multiple-dose (2) administration.
According to the European label for HES 130/0.4 and the United States hetastarch label, these can be used in patients with non-oligoanuric renal impairment. Therefore, information on the dependency of pharmacokinetics of HES on renal function is a crucial contribution to increase therapeutic safety, and was assessed in this study for HES 130/0.4 (6%).
Methods
After approval of the study by the local ethics committee, subjects gave written informed consent for their participation. All procedures were performed according to Good Clinical Practice standards. Nineteen volunteers (6 women, 13 men) with different degrees of stable, non-anuric renal dysfunction were included. Phase I facilities and volunteer database (Pharm PlanNet Clinical Pharmacology Institute, Moenchengladbach, Germany) were used. Subject recruitment followed a predefined stratification according to the Food and Drug Administration guidance document (15) to cover a wide range of renal impairment, and to allow for regression analysis rather than comparing arbitrary renal function groups only. Six subjects belonged to the group with "severe" renal impairment (creatinine clearance
), 4 to "moderate" (30 -Ͻ50), 5 to "mild" (50 -Ͻ80), and 4 almost normal subjects showed a CL cr in the interval 80 -Ͻ120. Stable renal function was verified by performing at least 2 separate measurements of CL cr using 24-h urine collection and a serum sample. Creatinine was measured by the Jaffé method. The standard formula was applied for CL cr determination: urine concentration · urine volume · body surface area ⅐ serum concentration Ϫ1 · 1.73 m Ϫ2 · 1440 min
Ϫ1
. The mean of both values was taken before the subjects were assigned to their respective stratum. Volunteers with unstable renal function, severe hepatic or cardiac disease, or severe anemia were not included in the study.
Under supervision of an anesthesiologist, 500 mL of 6% HES 130/0.4 solution (Voluven ® ; Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany) was infused over a 30-min period by using an infusion pump. Venous blood samples were drawn into lithium heparinized tubes before the start of infusion, 5, 10, and 30 min, 1, 2, 4, 6, 8, 24, 48, and 72 h after the start of infusion. Urine samples were collected quantitatively up to 96 h.
The HES either in plasma or urine samples was precipitated by acetone. After the removal of the supernatant, HES precipitate was dissolved in sodium azide solution and hydrolyzed into glucose with trifluoroacetic acid. After drying and dissolving in buffer solution, the glucose was determined enzymatically with a glucose analyzer. The determination of in vivo mean Mw was performed by using low-angle laser lights scattering and high-performance liquid chromatography validated for physiologic samples.
The primary objective of this study was to investigate whether renal impairment had an effect on the pharmacokinetics of HES. Significance tests were exploratively applied each at nominal ␣-level of 5% and referred to the null-hypothesis of zero correlation.
This was statistically addressed by exploring the relationship between CL cr and each of the pharmacokinetic variables applying correlation and regression analyses. A subject was judged valid for analysis if CL cr was found stable during the screening phase showing values between 15 and Ͻ120 mL · min Ϫ1 · 1.73 m
Ϫ2
, and if primary pharmacokinetic variables (area under the time concentration curve [AUC (0 -inf) ] and peak concentration [C max ]) could be derived from the analytic blood sample profile.
Correlation analyses were also performed to investigate the relationship between CL cr , age, body mass index, height, weight, and the pharmacokinetic variables (both model independent and model based) calculating Pearson correlation coefficients. This also included consideration of partial correlations that describe the association between two variables controlling for other potentially confounding variables. In addition, HES mean Mw, baseline CL cr , and serum amylase were also the subject of partial correlation analyses.
Descriptive statistics were calculated for each of the pharmacokinetic variables, including geometric means and corresponding coefficients of variation.
In addition, two predefined subgroups with CL cr Յ50 and Ͼ50 mL · min Ϫ1 · 1.73 m Ϫ2 were compared with respect to AUC (0 -inf) and C max . Log-transformed variables were submitted to separate analyses of variance including the fixed effects sex, subgroup, and interaction sex · subgroup. Point estimates and associated (explorative) two-sided 95% confidence intervals were constructed for the ratio of the two subgroups (Յ50/Ͼ50 mL · min Ϫ1 · 1.73 m Ϫ2 ). Based on previous information, the coefficient of variation (CV) of AUC (0 -inf) was assumed to be approximately 20%. This means that a difference of approximately 35% between two subgroups consisting of 9 subjects each could be detected with 80% power at an explorative ␣-level of 5%. In fact, the (pooled within-group) CV was 19% for AUC (0 -inf) and 22% for C max so that this study was adequately powered to provide valid and credible results. Data were analyzed by using SAS ® version 6.12 (SAS Institute Inc., Cary, NC). Pharmacokinetic variables were derived by using WinNonLin™ version 3.0 (Pharsight Corp., West El Camino Real, CA) for both the model independent approach and the twocompartmental modeling.
Safety was investigated by documentation of adverse events (AE), routine clinical laboratory, physical examination, blood pressure (BP), pulse rate, and electrocardiogram. Specifically, determination of CL cr from 24-h urine (day 3, 4) was performed twice after drug exposition. Cumulative HES excretion and residual HES plasma concentrations were regarded as especially relevant for product safety, in addition to the primary pharmacokinetic variables AUC (0 -inf) and C max .
Results
All subjects were valid for pharmacokinetic evaluation. Means ; all other CVs were less than 17%. Increased restriction of renal function was associated with older age and higher baseline systolic BP. For 8 of the 15 subjects with CL cr values Ͻ80, the etiology of the impaired renal function was not known. For two subjects, diabetes mellitus was reported as the underlying disease. Each of the diagnoses, immunoglobulin A (IgA)-neuropathy, nephrolithiasis, sarcoidosis, suspected hypertensive nephropathy, and polycystic kidney disease, was documented once.
HES plasma concentrations were larger in the 10 subjects with CL cr Ͻ50 than in the 9 subjects with CL cr Ͼ50. Figure 1 shows the mean courses of HES concentration up to 72 h after infusion. Table 1 shows the most relevant pharmacokinetic variables. No differences were apparent when comparing the two renal groups (15-Ͻ30) and (30 -Ͻ50). The same is true for a comparison between the renal groups (50 -Ͻ80) and (80 -Ͻ120).
The study showed that AUC (0 -inf) , and consequently HES total plasma clearance, clearly depended on renal function (i.e., on CL cr ). Figure 2 displays the correlation between baseline Cl cr and AUC (0 -inf) . The coefficient of correlation was calculated as Ϫ0.76 being significantly different from zero (P Ͻ 0.001). This relationship seemed even stronger when controlling for the potentially influencing factors of age, body mass index, height, and weight: the corresponding partial correlation coefficient resulted to Ϫ0.89.
Subjects with a CL cr Ͻ50 had, on average, a 73% larger AUC (0 -inf) than subjects with a CL cr Ͼ50. The 95% confidence interval for the mean AUC ratio of 1.73 was 1.44, 2.07, which indicated that a more than doubled AUC in moderate-to-severe renally impaired subjects can be excluded.
Inversely, HES total plasma clearance decreased with decreasing baseline CL cr (Fig. 3) ; however, the proportional decrease was less than expected from the reduction in CL cr for a compound such as HES, which is glomerularly filtered only.
The plasma C max was not affected by renal impairment (r ϭ Ϫ0.07, P ϭ 0.77). Also, renal impairment did not influence terminal half-life, which was on average 16.1 h and ranged between 14.1 and 18.9 h (r ϭ 0.31, P ϭ 0.19).
The cumulative amount of drug excreted into urine within 72 to 96 h was 59% of the total dose infused in subjects with a CL cr Ͼ30, whereas it was 51% in the severely impaired group (15-Ͻ30 mL · min Ϫ1 · 1.73 m
Ϫ2
; Fig. 4 ). HES pharmacokinetics are often described using a two-compartmental model (14) . The two-compartmental model also provided a valid fit to the individual HES plasma concentration-versus-time curves in this study.
The ␣ half-life (t1/2␣) was prolonged by impaired renal function. In subjects with a CL cr between 80 and 120, mean t1/2␣ was calculated as 0.6 h compared with 1 h in the group with CL cr between 50 and 80, and to approximately 1.5 h in subjects with a CL cr Ͻ50 (mL · min Ϫ1 · 1.73 m Ϫ2 ). A linear relationship between t1/2␣ and CL cr could be assumed, showing a correlation coefficient of r ϭ Ϫ0.55 (P ϭ 0.02). Corresponding results were obtained for drug elimination half-life from the central compartment: means of 2 h for (80 -Ͻ120), 3 h for (50 -Ͻ80), and approximately 5 h for CL cr Ͻ50. Half-life (central compartment) linearly increased with decreasing CL cr , showing an r ϭ Ϫ0.73 (P Ͻ 0.001). Mean t1/2␤ resulted in 9.7 h. An influence of renal impairment on t1/2␤ was not detected (r ϭ Ϫ0.37, P ϭ 0.12).
The mean Mw of the original 6% solution was analyzed as 130,652 d. In the first sample taken (after 0.5 h), mean Mw was 62,704 d, and in the second HES ϭ hydroxyethyl starch, CV ϭ coefficient of variation, CI ϭ confidence interval, AUC ϭ area under the time concentration curve, C max ϭ peak concentration.
a Defined according to measurements of creatinine clearance (mL/min/1.73 m 2 ).
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sample (after 1 h), the mean value was 59,117 d. However, the Mw tended to decrease with decreasing baseline CL cr (r ϭ 0.63, P ϭ 0.04 after 0.5 h). Baseline serum amylase was inversely correlated with CL cr (r ϭ Ϫ0.72, P Ͻ 0.001), and Mw in plasma after 1 h was also inversely correlated with baseline amylase (r ϭ Ϫ0.76, P Ͻ 0.001) (Fig. 5 ). In subjects with higher baseline amylase, lower HES Mw after 1 h can be regarded as an indicator of accelerated intravascular breakdown, because there was no indication that the lower plasma Mw was caused by a selective retention of smaller HES molecules in these subjects. In fact, partial correlation analysis provided evidence for an association between baseline amylase activity in the metabolism of HES independent of CL cr .
There was no deterioration in renal function after dosing, as determined by repetitive CL cr measurements in the individual subjects. On average, CL cr even increased by 7.8 mL · min Ϫ1 · 1.73 m Ϫ2 (sd ϭ 16.6, P ϭ 0.054) from prestudy to poststudy. All AE had been recorded throughout the study, whether or not causally related. There was no drop-out. Eight of 19 subjects experienced 17 AE, none of them serious or otherwise important, all lasting Ͻ24 h, except for urinary infection. Headache, nausea, transient vision disturbances, and precordial pressure (all rated as "mild") were classified as possibly related to the study medication, but could alternatively be explained by the volunteer setting. The other AE had an unlikely relationship to the study drug. Interestingly, there was no AE at all in the worst renal function group (CL cr 15-Ͻ30).
Amylase increased postdose, which however was judged as clinically irrelevant (predose mean: 62.5; 8 h: 96.9; 24 h: 75.4; 48 h: 65.4 U/L), because this is a well known effect for HES based on the formation of macro-amylase (16), which is excreted more slowly and not related to pancreatic dysfunction. The transient, induced amylase increase did not correlate with in vivo Mw (data not shown), as opposed to the correlation of baseline amylase and Mw described above. Overall, no clinically relevant laboratory changes occurred. Also, the coagulation variables studied were unremarkable: partial thromboplastin time 35 Ϯ 6 s at 8 h (baseline 33 Ϯ 6 s), thrombin time 16 Ϯ 1 s at 8 h (16 Ϯ 1 s), and platelets 237 Ϯ 49/nL (238 Ϯ 54/nL).
Discussion
The pharmacokinetics of HES 130/0.4 were evaluated in subjects with stable renal insufficiency. HES 130/0.4 was developed to improve pharmacokinetics of current medium Mw HES whereas maintaining efficacy. Studies in healthy volunteers after single (14) and multiple administration of 500 mL for 10 days (2) showed rapid renal excretion and no plasma accumulation. In contrast, older starches, such as HES 450/0.7 accumulate in plasma after multiple infusions (17, 18) . This has been known since the 1970s, but is often not acknowledged. Large residual concentrations of colloid after 24 hours should be avoided, because they are not expected to exert a relevant therapeutic effect, but could be related to potential side effects.
In this study, we found residual concentrations 24 hours after 500 mL HES 130/0.4 to be small, even in subjects with severe renal dysfunction. In the worst renal function group (CL cr [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , the mean HES plasma concentration at 24 hours was 0.5 mg/mL. Persisting large plasma concentrations beyond the duration of volume effect (which lasts 4 -6 hours in the case of HES 130/0.4) (19) should be avoided, because potential harm will not be balanced by the benefit. As a comparison, 24 hours after the same amount of hetastarch (450/0.7, 6%) was given to volunteers with normal renal function, the concentration was 4 mg/dL (17) . In a recent study with pentastarch (200/0.5, 500 mL, 10%), approximately 1.5 mg/dL HES was found in plasma after 24 hours, again in normal volunteers (20) . Hence, residual plasma concentrations after 24 hours in our subjects with mild-to-severe renal impairment were smaller than those in normal volunteers after hetastarch or pentastarch in the cited studies.
In a pilot study, Gassmayr et al. (21) revealed no clinically relevant differences in half-time and plasma HES concentrations using a single HES 200/0.5 (10%) infusion in patients with renal impairment compared with healthy subjects; therefore, no undue risks with an improved HES specification were to be expected.
The current study with HES 130/0.4 for the first time gives extensive pharmacokinetic data of a HES in dependency of well defined, stable, non-anuric renal dysfunction. C max and terminal half-life were not dependent on renal function, whereas AUC increased moderately. HES total plasma clearance in renal dysfunction decreased less than expected from the reduction in CL cr . This might be attributed to the higher baseline amylase levels in subjects with renal dysfunction, because higher baseline amylase levels were also associated with lower in vivo Mw, indicating increased HES metabolism. Data analysis showed that the effect of amylase can be postulated as independent of baseline renal function although both amylase and Mw were closely related with baseline renal function expressed as CL cr . Thus, the results suggest that the increased baseline amylase levels (caused by the renal insufficiency itself) in part compensated for the reduced glomerular filtration rate, explaining the higher than expected HES clearance. The infusion volume was fixed to 500 mL in all subjects to allow comparability to the previous data generated in normal volunteers (14) . Because the four groups were comparable with regard to body weight, the individual differences concerning the dose per kilogram of body weight did not affect the study results and conclusions presented in this report. A limitation of all pharmacokinetic studies with colloidal infusion solutions is that they influence their own volume of distribution (which was not a primary variable of this study) because of their volume-expanding effect. Overall, HES 130/0.4 in subjects with mild-to-severe renal impairment showed excellent urinary excretion compared with HES 130/0.4 in healthy volunteers (14) , and small residual plasma concentrations after 24 h when compared with other HES preparations in healthy volunteers.
After our single-dose application, we found no deterioration in renal function, as measured by CL cr determination in duplicate after exposition. Dehne et al. (22) did not find an effect of HES on renal function or sensitive tubular markers in surgical patients without prior renal impairment. Kumle et al. (23) studied the influence of 3 different intravascular volume replacement regimens (HES 70/0.5, HES 200/0.5, and gelatin) on renal function in elderly patients without prior renal dysfunction undergoing major abdominal surgery. As assessed by sensitive markers of renal function, all three regimens could be used safely for volume replacement without renal dysfunction. Schortgen et al. (24) compared HES 200/0.62 (6%) to a 3% gelatin solution in patients with severe sepsis, and described HES 200/0.62 to be a risk factor for deterioration of renal function. However, as noted in several letters (25) , the conclusions of that study should not be generalized. Baseline renal function is a known major risk factor for the development of postoperative renal dysfunction, as determined in many other studies (26 -28) .
Among the HES solutions, it is important to differentiate between those with a longer-lasting volume effect accompanied by plasma accumulation after repetitive use (high Mw and/or highly substituted, HES 450/0. Residual HES plasma concentrations after 24 hours were small. Considering these and the pharmacokinetic results of this study, we conclude that HES 130/ 0.4 (500 mL 6%) can be administered to patients even with severe renal impairment, as long as urine flow is preserved, without the risk of plasma accumulation. Further studies in renally impaired patients in the perioperative setting and in intensive care are justified.
